Sex differences in alpha-1-antitrypsin deficiency lung disease-analysis from the German registry

Figures & data

Table 1.  Clinical characteristics of patients of the gAATDR

	Total	Male	Female	P (male vs. female)
Subjects	1066	482	584	—
Age at entry	52.28 (13.66)	51.91 (13.86)	52.76 (13.39)	n.s.
BMI	24.09 (5.26)	24.59 (5.178)	23.50 (5.203)	n.s.
Age at diagnosis	47.32 (16.68)	46.53 (14.55)	48.34 (14.80)	n.s.
Age at symptom begin	40.78 (12.56)	40.72 (12.13)	40.89 (13.17)	n.s.
Reason for genotyping
Lung disease	789 (72.52)	460 (80.99)	329 (74.77)	—
Liver disease	38 (3.49)	26 (5.58)	12 (2.73)	—
Other disease	27 (2.48)	15 (2.64)	12 (2.73)	—
Family screening	102 (9.38)	43 (7.57)	59 (13.41)	—
Population screening	2 (0.18)	0 (0.00)	2 (0.45)	—
Other	50 (4.60)	24 (2.23)	26 (5.91)	—

Data are presented as mean ± SD for continuous data or n (%) for categorical data.

Table 2.  Distribution of age, BMI, pack-years, post-bronchodilator FEV₁% pred., exacerbations/2 years, and SGRQ between male and females COPD patients stratified by spirometric COPD stages

		GOLD I N = 47 (19/28)	GOLD II N = 160 (84/77)	GOLD III N = 163 (111/52)	GOLD IV N = 51 (37/14)
Age	m	62. 58 (9.67)	52.89 (13.02)	51.73 (11.40)	49.03 (9.80)
	f	60.21 (12.82)	57.38 (10.56)	52.46 (7.62)	47.57 (8.22)
BMI p < 0.05	m	25.21 (3.56)	24.50 (3.69)	24.93 (4.12)	23. 02 (4.21)
	f	24.23 (5.43)	23.71 (4.01)	24.35 (6.72)	22.43 (3.03)
Pack-years p < 0.05	m	8.90 (9.30)	15.68 (15.84)	20.01 (18.34)	21.30 (14.93)
	f	5.71 (10.96)	10.98 (12.81)	16.21 (15.11)	14.35 (20.23)
FEV1% post	m	96.17 (14.35)	62.46 (9.22)	39.74 (5.93)	22.37 (5.12)
	f	95.22 (14.24)	61.84 (8.55)	39.42 (5.47)	24.35 (5.25)
Exacerbations/2 years	m	0.78 (1.06)	0.66 (1.52)	0.79 (0.97)	1.47 (1.06)
	f	0.68 (0.98)	0.86 (1.07)	0.67 (1.75)	1.23 (1.36)
SGRQ	m	37.41 (17.81)	43.37 (17.69)	51.51 (17.82)	59.91 (15.37)
	f	37.37 (18.80)	49.12 (18.90)	50.94 (17.13)	55.29 (21.27)

Significances (t-test) refer to the combined groups GOLD I-IV. m = male, f = female.